Q32 Bio (QTTB) Current Deferred Revenue (2017 - 2023)
Q32 Bio (QTTB) posted quarterly Current Deferred Revenue of $354000.0 for Q1 2023, down 88.97% year-over-year from $3.2 million in Q1 2022, and down 69.38% quarter-over-quarter from $1.2 million in Q4 2022.
Q32 Bio (QTTB) Current Deferred Revenue (2017 - 2023) Analysis & Trends
Q32 Bio's Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $354000.0 for Q1 2023.
- In Q1 2023, Current Deferred Revenue fell 88.97% year-over-year to $354000.0; the TTM figure through Mar 2023 stood at $354000.0 (down 88.97% YoY), while the FY2022 annual figure was $1.2 million, down 63.97% from the prior year.
- Current Deferred Revenue for Q1 2023 stood at $354000.0, down from $1.2 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $5.6 million in Q4 2020, with the low at $354000.0 in Q1 2023.
- The 5-year median for Current Deferred Revenue is $1.2 million (2021), against an average of $2.1 million.
- The sharpest annual moves came in 2020 and 2023: Current Deferred Revenue soared 596.17% in 2020, then slumped 88.97% in 2023.
- Q32 Bio's Current Deferred Revenue stood at $809000.0 in 2019, then jumped by 596.17% to $5.6 million in 2020, then slumped by 43.04% to $3.2 million in 2021, then tumbled by 63.97% to $1.2 million in 2022, then plunged by 69.38% to $354000.0 in 2023.
- Business Quant data shows QTTB's Current Deferred Revenue at $354000.0 in Q1 2023, $1.2 million in Q4 2022, and $2.0 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 354,000.00 |
| Dec 31, 2022 | 1.16 Mn |
| Sep 30, 2022 | 1.96 Mn |
| Jun 30, 2022 | 2.76 Mn |
| Mar 31, 2022 | 3.21 Mn |
| Dec 31, 2021 | 3.21 Mn |
| Sep 30, 2021 | 3.21 Mn |
| Jun 30, 2021 | 1.20 Mn |
| Mar 31, 2021 | 5.18 Mn |
| Dec 31, 2020 | 5.63 Mn |
| Sep 30, 2020 | 2.94 Mn |
| Jun 30, 2020 | 774,000.00 |
| Mar 31, 2020 | 774,000.00 |
| Dec 31, 2019 | 809,000.00 |
| Sep 30, 2019 | 774,000.00 |
| Jun 30, 2019 | 1.16 Mn |
| Mar 31, 2019 | 905,000.00 |
| Dec 31, 2018 | 770,000.00 |
| Sep 30, 2018 | 3.61 Mn |
| Jun 30, 2018 | 3.50 Mn |